Research programme: cancer pain therapeutics - Benitec

Drug Profile

Research programme: cancer pain therapeutics - Benitec

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Benitec Ltd
  • Developer Benitec Biopharma
  • Class Small interfering RNA
  • Mechanism of Action D amino acid oxidase inhibitors; Gene silencing; Protein kinase C gamma inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-pain in Australia (Intrathecal, Injection)
  • 18 May 2011 Preclinical trials in Cancer pain in Australia (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top